2006 Proteoglycans Gordon Research Conferences

描述（由申请人提供）： 第12届戈登蛋白聚糖会议将于7月9日至14日在美国新罕布什尔州安多弗的普罗克特学院举行。本次会议的目的是将来自世界各地的蛋白聚糖研究界的成员聚集在一起，介绍和讨论蛋白聚糖的结构，功能和遗传学的最新发现，特别关注疾病机制中的信号传导。会议将继续发挥其在过去20年中作为该研究界增长的催化剂所发挥的主导作用。蛋白聚糖研究小组包括来自学术、政府和企业实验室的化学、细胞生物学、生物化学、工程和临床领域的全球专家。该计划涵盖的主要主题包括1）糖胺聚糖的生物合成和结构，2）糖胺聚糖在生长因子和趋化因子信号传导中的结构-活性，3）肌肉骨骼系统中的蛋白聚糖信号传导，4）细胞信号传导机制中的蛋白聚糖，5）发育中的蛋白聚糖，6）损伤和炎症中的蛋白聚糖，7）癌症中的蛋白聚糖，和8）疾病模型中的蛋白聚糖。我们计划举行9次会议，共31次全体会议，每次会议由一位该领域的知名专家主持。全体会议的发言人是以代表该领域最新研究结果的主要目标而选择的。此外，会议将鼓励“新面孔”的参与，即来自其他领域或疾病专业的专家，他们在其专业领域发现了蛋白聚糖的新作用，或者是在国际舞台上新出现的新战略或见解的发言人。此外，还将从提交的摘要中选出另外20-25个简短的演讲，为具有新的和令人兴奋的发现的与会者提供发言机会，为新的和代表性不足的研究人员提供机会，并涵盖全体会议上代表性不足的主题。讲座将辅以积极的海报会议和讨论。总之，参加本次会议的研究人员将来自各个级别，包括目前由NIAMS、NCI、NIDCR、NINDS、NHLBI、NIA、NIDDK、NICHD、NIGMS、NCCR和其他NIH研究所资助的研究人员。按照本次会议的传统，大约三分之一的计划演讲将报告蛋白聚糖在炎症和关节炎以及其他肌肉骨骼系统和骨骼疾病相关机制中的作用的新数据;主要重点也将放在蛋白聚糖在癌症侵袭和肿瘤血管生成的细胞生物学，以及血管系统和心脏，肾脏，大脑，和皮肤。重点也将给予蛋白多糖信号机制和器官发育。会议的高潮将是两次会谈，重点是新的发现方法和基于新发现机制的新药设计方法。会议的目的是促进与人类疾病蛋白聚糖研究相关的新发现，概念和技术的交流。预期会议的成果将是增进对许多人类疾病的了解，包括人类发展、肌肉骨骼系统、神经系统、血管系统、免疫和癌症等疾病，而这种了解将最终导致研制出防治这些疾病的新药。

DESCRIPTION (provided by applicant): The 12th Gordon Conference on Proteoglycans will be held July 9th-14th at Proctor Academy in Andover, New Hampshire, USA. The purpose of this meeting will be to bring together members of the proteoglycan research community from around the world to present and discuss the most recent discoveries in the structure, function, and genetics of proteoglycans, with particular focus on signaling in disease mechanisms. The conference will continue the leading role that it has played over the past 20 years in serving as a catalyst for growth in this research community. The proteoglycan research group includes worldwide experts in chemical, cell biological, biochemical, engineering and clinical areas from academic, government and corporate laboratories. The major themes to be covered in the program include 1) Biosynthesis and Structure of Glycosaminoglycans, 2) Structure-Activity of Glycosaminoglycans in Growth Factor and Chemokine Signaling, 3) Proteoglycan Signaling in the Musculoskeletal System, 4) Proteoglycans in Cell Signaling Mechanisms, 5) Proteoglycans in Development, 6) Proteoglycans in Injury and Inflammation, 7) Proteoglycans in Cancer, and 8) Proteoglycans in Disease Models. We have planned nine sessions with a total of 31 plenary talks, with each session chaired by a known expert in the field. The speakers for the plenary talks are chosen with the primary goal of representing the top recent findings in the field. Additionally, the conference will encourage the participation of "new faces," namely, experts from other fields or disease specialties that have discovered new roles for proteoglycans in their area of expertise, or are speakers that are newly emerging on the international stage with new strategies or insights. In addition, another 20-25 short talks will be selected from the submitted abstracts, providing speaking opportunities for conferees with new and exciting findings, to provide opportunities for newer and underrepresented investigators, and to cover topics underrepresented in the plenary talks. The talks will be supplemented by active poster sessions and discussions. In all, investigators participating in this conference will be at all levels, including investigators currently funded by NIAMS, NCI, NIDCR, NINDS, NHLBI, NIA, NIDDK, NICHD, NIGMS, NCCR and other NIH Institutes. As has been the tradition at this conference, approximately a third of the planned presentations will report novel data on the role of proteoglycans in mechanisms relevant to inflammation and arthritis and other diseases of the musculoskeletal system and bone; major emphasis will also be given to proteoglycans in the cell biology of cancer invasion and tumor angiogenesis, and diseases of the vascular system and heart, and kidney, brain, and skin. Emphasis will also be given to proteoglycan signaling mechanisms and organ development. The culmination of the meeting will be two talks focused on new methodologies of discovery and approaches for new drug design based on newly discovered mechanisms. The goal of the conference is to promote the exchange of new findings, concepts and technology related to proteoglycan research into human disease. It is anticipated that the outcome of the conference will be an enhanced understanding of numerous human diseases, including those of human development, the musculoskeletal system, nervous system, vascular system, immunity and cancer, and that this understanding will ultimately lead to the formulation of new drugs for combating these diseases.